Biotech Values

[jq1234]

This is yet another prime example of cross-trial comparison and why FDA has resisted Bayesian analysis in drug trials.

I agree. The question to me is why AMLN/LLY conducted the trial in the first place? What did they want to prove? If the trial met primary endpoint, Bydureon were non-inferior to Victoza, so what? I think it is an example of bad decision making.